|
2025
|
Invention
|
Glatiramer depot systems for treating progressive forms of multiple sclerosis.
The present inven... |
|
2024
|
Invention
|
Treatment of primary progressive multiple sclerosis. The present invention provides compositions ... |
|
|
Invention
|
Depot systems comprising cariprazine or salts thereof. The present invention provides long-acting... |
|
2023
|
Invention
|
Semaglutide depot systems and use thereof.
The present invention provides parenteral pharmaceuti... |
|
|
Invention
|
Depot systems comprising cariprazine or salts thereof. in situin situ implants suitable for subcu... |
|
2022
|
Invention
|
Process for preparing microparticles containing glatiramer acetate. The present invention provide... |
|
|
Invention
|
Depot systems comprising glatiramer or pharmacologically acceptable salt thereof. Long acting par... |
|
|
Invention
|
Semaglutide depot systems and use thereof. The present invention provides parenteral pharmaceutic... |
|
2021
|
Invention
|
Method for suppressing or alleviating primary or secondary progressive multiple sclerosis (ppms o... |
|
|
Invention
|
Extended release dosage forms of pregabalin.
The present invention relates to extended-release p... |
|
|
Invention
|
Low burst-release liraglutide depot systems.
The present invention provides parenteral pharmaceu... |
|
|
Invention
|
Low burst-release liraglutide depot systems. The present invention provides parenteral pharmaceut... |
|
2018
|
Invention
|
Methods for suppressing or alleviating primary or secondary progressive multiple sclerosis (ppms ... |
|
|
Invention
|
Glatiramer depot systems for treating progressive forms of multiple sclerosis. The present invent... |
|
2017
|
Invention
|
Depot systems comprising glatiramer acetate. The present invention provides compositions and meth... |
|
|
Invention
|
Extended release dosage forms of pregabalin. The present invention relates to extended-release ph... |
|
|
Invention
|
Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cell... |
|
|
Invention
|
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells. Metho... |
|
|
Invention
|
Treatment of multiple sclerosis with long acting glatiramer and adipose-derived stem cells.
|
|
2016
|
Invention
|
Amorphous form of selexipag. The present invention provides a stable amorphous form of selexipag,... |
|
2015
|
Invention
|
Sublingual delivery of glatiramer acetate. The present invention provides Glatiramer acetate comp... |
|
|
Invention
|
Intermediate compounds and process for the preparation of efinaconazole. The present invention re... |
|
|
Invention
|
Intermediate compounds and process for the preparation of efinaconazole. The present invent... |
|
|
Invention
|
Process and intermediates for the preparation of perampanel. The present invention describes a pr... |
|
2014
|
Invention
|
Polymorphs of darunavir. The present invention provides new pseudopolymorphic forms of darunavir ... |
|
|
Invention
|
Intermediate compounds and processes for the preparation of quinoline derivatives such as laquini... |
|
|
Invention
|
Amorphous form of apremilast. The present invention provides a new amorphous form of apremilast, ... |
|
|
Invention
|
Co-crystals of dapagliflozin. The present invention provides novel co-crystal forms of dapagliflo... |
|
2013
|
Invention
|
Polymorphs of perampanel. The present invention provides novel crystalline forms of perampanel, p... |
|
2012
|
G/S
|
Pharmaceutical preparations for use in the treatment of
diseases, veterinary preparations for th... |
|
|
G/S
|
Pharmaceutical and veterinary preparations; medical
diagnostic reagents for clinical or medical ... |
|
|
Invention
|
Amorphous form of dolutegravir. An amorphous form of dolutegravir sodium, pharmaceutical composit... |
